AZD2624

Ligand id: 5775

Name: AZD2624

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 8
Topological polar surface area 96.54
Molecular weight 459.16
XLogP 8.15
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

Classification
Compound class Synthetic organic
IUPAC Name
3-methanesulfonamido-2-phenyl-N-[(1S)-1-phenylpropyl]quinoline-4-carboxamide
Synonyms
AZD4901 | MLE4901
Database Links
CAS Registry No. 941690-55-7
GtoPdb PubChem SID 178102400
PubChem CID 23649245
Search Google for chemical match using the InChIKey QYTBBBAHNIWFOD-NRFANRHFSA-N
Search Google for chemicals with the same backbone QYTBBBAHNIWFOD
Search UniChem for chemical match using the InChIKey QYTBBBAHNIWFOD-NRFANRHFSA-N
Search UniChem for chemicals with the same backbone QYTBBBAHNIWFOD
Comments
AZD2624 is an orally active antagonist of neurokinin receptor 3 (TACR3) developed initially by AZ as a potential therapeutic for schizophrenia. This compound was included in AstaZeneca's Open Innovation Pharmacology Toolbox (but has since been removed). Later renamed to AZD4901 it was acquired by Millendo Therapeutics who gave it a new research code of MLE4901 for their development programs for polycystic ovary syndrome and menopausal hot flushes. A successful Phase II study for the latter indication was reported in April 2017 [4]. A total of eight analogues are disclosed in the AZ composition of matter filing [5],